Dataset: Expression data from EGFR WT or EGFR mutant NSCLC with or without erlotinib

Non-small cell lung cancers (NSCLCs) harboring activating EGFR mutants show dramatic responses to EGFR TKIs, such as erlotinib and geffitinib. However, nearly all patients show relapse within 1 year after initial treatment. We used microarrays to detail global gene expression changes in EGFR mutant cells vs. WT cells responding to erlotinib. 4 EGFR mutant and 4 WT NSCLC cells were treated with or without erlotinib for 24 hr, followed by RNA extraction and hybridization on Affymetrix microarrays.

Species:

human

Samples:

32

Source:

E-GEOD-57156

Updated:

Dec.12, 2014

Registered:

Jul.10, 2014